The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|January 2, 2022
- Pharmaceutical Technology, January 2022 Issue
- Volume 46
- Issue 1
Next-Generation Cas9 Proteins
Author(s)Pharmaceutical Technology Editors
Thermo Fisher's Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency.
Thermo Fisher Scientific’s Invitrogen TrueCut Hifi Cas9 Protein is designed for research applications that require highly precise genome editing, such as the engineering of chimeric antigen receptor (CAR)-T cells and the creation of cellular models for disease discovery.
The Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency. It does this by minimizing edits in unintended locations, which are disruptive in translational research, drug screening, and drug modeling. It has demonstrated near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs), as well as shown improved off-target profiles relative to similar proteins.
Articles in this issue
almost 5 years ago
Industrious Pharmaceuticalsalmost 5 years ago
The Long Path to Normalalmost 5 years ago
Changes Afoot: 2022 Outlook for Pharma and its Peoplealmost 5 years ago
Addressing the Training Gap for Single-Use Technologiesalmost 5 years ago
The Need for Speed: How Operation Warp Speed Shifted the Pharma Industryalmost 5 years ago
Taste and Appearance: Selecting the Right Excipientsalmost 5 years ago
Tackling the Big Issue of Solubilityalmost 5 years ago
Biologics Testing Highlights Need for Analytical Skillsalmost 5 years ago
Outsourcing’s Race Toward Noveltyalmost 5 years ago
Regulating Digital TherapeuticsRelated to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.